NCT01703507View on ClinicalTrials.gov

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 9, 2012

Primary Completion Date

May 20, 2015

Study Completion Date

April 11, 2018

Conditions
Recurrent MelanomaStage IV MelanomaTumors Metastatic to Brain
Interventions
DRUG

Ipilimumab

Given IV

RADIATION

Whole-Brain Radiation Therapy (WBRT)

Undergo WBRT

RADIATION

Stereotactic Radiosurgery (SRS)

Undergo SRS

Trial Locations (2)

19107

Thomas Jefferson University, Philadelphia

43210

Ohio State University, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT01703507 - Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma | Biotech Hunter | Biotech Hunter